Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies

P. Comella, G. Palmieri, V. Lorusso, G. Catalano, D. Nicollela, G. P. Ianniello, R. Casaretti, M. Montella, G. Frasci, M. Perna, G. Comella

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the activity and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by means of methotrexate (MTX) and levo-folinic acid (LFA) in patients with advanced carcinoma of the digestive tract, and to assess the prognostic significance of MTX serum concentrations achieved in these patients. 94 patients affected by advanced carcinoma of the colon-rectum, stomach or biliary tract (47 of them previously untreated) received a regimen consisting of MTX 500 mg/m2 as a 2-h i.v. infusion on day 1, followed by LFA 250 mg/m2 as a 2-h i.v. infusion and 5-FU 600 mg/m2 as an i.v. bolus on day 2. Cycles were repeated every 2 weeks. Treatment was administered until tumour progression or for a maximum of 24 courses. MTX serum level was assessed soon after and 24 h (24-h MTXs) after its infusion in 61 patients. One complete and 22 partial responses were obtained, giving an overall activity of 24% (95% confidence interval, 16-34%). Response rate was 30% in chemotherapy-naive patients (colorectal, 26%; gastric, 37%; and biliary-tract, 22%) and 19% in those previously treated (all with fluoropyrimidines). A poor performance status adversely affected the response and survival of patients. The toxicity of treatment was very mild, and occurrence of severe diarrhoea (11% of patients) and mucositis (3%) was lower than that reported with other modulations of 5-FU. A cut-off value of 24-h MTXs was identified as a strong prognostic indicator. Patients with 24-h MTXs ≤ 2 μM had a significantly better probability of response (37% versus 5%; P = 0.032), longer progression-free survival (5.3 versus 2.3 months; P = 0.023) and overall survival (10.8 versus 8.3 months; P = 0.045) on multivariate analysis. In chemotherapy-naive colorectal cancer patients, those with 24-h MTXs ≤ 2 μM had a response rate of 38% (3/8), with a 19.6-month median survival time, as compared to no responses (0/4) and a 9.9-month median survival in the group with a lower serum concentration. The achievement of such MTX serum levels yielded a 31% (4/13) response rate even in colorectal patients who had previously received a 5-FU-FA treatment.

Original languageEnglish
Pages (from-to)1719-1726
Number of pages8
JournalEuropean Journal of Cancer
Volume32
Issue number10
DOIs
Publication statusPublished - Sep 1996

Fingerprint

Leucovorin
Methotrexate
Fluorouracil
Gastrointestinal Tract
Neoplasms
Therapeutics
Survival
Biliary Tract
Serum
Stomach
Carcinoma
Drug Therapy
Mucositis
Rectum
Disease-Free Survival
Colorectal Neoplasms
Diarrhea
Colon
Multivariate Analysis
Confidence Intervals

Keywords

  • 5-Fluorouracil
  • Double modulation
  • Gastrointestinal carcinomas
  • Levo-folinic acid
  • Methotrexate
  • Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. / Comella, P.; Palmieri, G.; Lorusso, V.; Catalano, G.; Nicollela, D.; Ianniello, G. P.; Casaretti, R.; Montella, M.; Frasci, G.; Perna, M.; Comella, G.

In: European Journal of Cancer, Vol. 32, No. 10, 09.1996, p. 1719-1726.

Research output: Contribution to journalArticle

@article{a79b93c5dc004b3a82fdfa7fec41d832,
title = "Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies",
abstract = "The aim of this study was to evaluate the activity and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by means of methotrexate (MTX) and levo-folinic acid (LFA) in patients with advanced carcinoma of the digestive tract, and to assess the prognostic significance of MTX serum concentrations achieved in these patients. 94 patients affected by advanced carcinoma of the colon-rectum, stomach or biliary tract (47 of them previously untreated) received a regimen consisting of MTX 500 mg/m2 as a 2-h i.v. infusion on day 1, followed by LFA 250 mg/m2 as a 2-h i.v. infusion and 5-FU 600 mg/m2 as an i.v. bolus on day 2. Cycles were repeated every 2 weeks. Treatment was administered until tumour progression or for a maximum of 24 courses. MTX serum level was assessed soon after and 24 h (24-h MTXs) after its infusion in 61 patients. One complete and 22 partial responses were obtained, giving an overall activity of 24{\%} (95{\%} confidence interval, 16-34{\%}). Response rate was 30{\%} in chemotherapy-naive patients (colorectal, 26{\%}; gastric, 37{\%}; and biliary-tract, 22{\%}) and 19{\%} in those previously treated (all with fluoropyrimidines). A poor performance status adversely affected the response and survival of patients. The toxicity of treatment was very mild, and occurrence of severe diarrhoea (11{\%} of patients) and mucositis (3{\%}) was lower than that reported with other modulations of 5-FU. A cut-off value of 24-h MTXs was identified as a strong prognostic indicator. Patients with 24-h MTXs ≤ 2 μM had a significantly better probability of response (37{\%} versus 5{\%}; P = 0.032), longer progression-free survival (5.3 versus 2.3 months; P = 0.023) and overall survival (10.8 versus 8.3 months; P = 0.045) on multivariate analysis. In chemotherapy-naive colorectal cancer patients, those with 24-h MTXs ≤ 2 μM had a response rate of 38{\%} (3/8), with a 19.6-month median survival time, as compared to no responses (0/4) and a 9.9-month median survival in the group with a lower serum concentration. The achievement of such MTX serum levels yielded a 31{\%} (4/13) response rate even in colorectal patients who had previously received a 5-FU-FA treatment.",
keywords = "5-Fluorouracil, Double modulation, Gastrointestinal carcinomas, Levo-folinic acid, Methotrexate, Pharmacokinetics",
author = "P. Comella and G. Palmieri and V. Lorusso and G. Catalano and D. Nicollela and Ianniello, {G. P.} and R. Casaretti and M. Montella and G. Frasci and M. Perna and G. Comella",
year = "1996",
month = "9",
doi = "10.1016/0959-8049(96)00155-4",
language = "English",
volume = "32",
pages = "1719--1726",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies

AU - Comella, P.

AU - Palmieri, G.

AU - Lorusso, V.

AU - Catalano, G.

AU - Nicollela, D.

AU - Ianniello, G. P.

AU - Casaretti, R.

AU - Montella, M.

AU - Frasci, G.

AU - Perna, M.

AU - Comella, G.

PY - 1996/9

Y1 - 1996/9

N2 - The aim of this study was to evaluate the activity and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by means of methotrexate (MTX) and levo-folinic acid (LFA) in patients with advanced carcinoma of the digestive tract, and to assess the prognostic significance of MTX serum concentrations achieved in these patients. 94 patients affected by advanced carcinoma of the colon-rectum, stomach or biliary tract (47 of them previously untreated) received a regimen consisting of MTX 500 mg/m2 as a 2-h i.v. infusion on day 1, followed by LFA 250 mg/m2 as a 2-h i.v. infusion and 5-FU 600 mg/m2 as an i.v. bolus on day 2. Cycles were repeated every 2 weeks. Treatment was administered until tumour progression or for a maximum of 24 courses. MTX serum level was assessed soon after and 24 h (24-h MTXs) after its infusion in 61 patients. One complete and 22 partial responses were obtained, giving an overall activity of 24% (95% confidence interval, 16-34%). Response rate was 30% in chemotherapy-naive patients (colorectal, 26%; gastric, 37%; and biliary-tract, 22%) and 19% in those previously treated (all with fluoropyrimidines). A poor performance status adversely affected the response and survival of patients. The toxicity of treatment was very mild, and occurrence of severe diarrhoea (11% of patients) and mucositis (3%) was lower than that reported with other modulations of 5-FU. A cut-off value of 24-h MTXs was identified as a strong prognostic indicator. Patients with 24-h MTXs ≤ 2 μM had a significantly better probability of response (37% versus 5%; P = 0.032), longer progression-free survival (5.3 versus 2.3 months; P = 0.023) and overall survival (10.8 versus 8.3 months; P = 0.045) on multivariate analysis. In chemotherapy-naive colorectal cancer patients, those with 24-h MTXs ≤ 2 μM had a response rate of 38% (3/8), with a 19.6-month median survival time, as compared to no responses (0/4) and a 9.9-month median survival in the group with a lower serum concentration. The achievement of such MTX serum levels yielded a 31% (4/13) response rate even in colorectal patients who had previously received a 5-FU-FA treatment.

AB - The aim of this study was to evaluate the activity and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by means of methotrexate (MTX) and levo-folinic acid (LFA) in patients with advanced carcinoma of the digestive tract, and to assess the prognostic significance of MTX serum concentrations achieved in these patients. 94 patients affected by advanced carcinoma of the colon-rectum, stomach or biliary tract (47 of them previously untreated) received a regimen consisting of MTX 500 mg/m2 as a 2-h i.v. infusion on day 1, followed by LFA 250 mg/m2 as a 2-h i.v. infusion and 5-FU 600 mg/m2 as an i.v. bolus on day 2. Cycles were repeated every 2 weeks. Treatment was administered until tumour progression or for a maximum of 24 courses. MTX serum level was assessed soon after and 24 h (24-h MTXs) after its infusion in 61 patients. One complete and 22 partial responses were obtained, giving an overall activity of 24% (95% confidence interval, 16-34%). Response rate was 30% in chemotherapy-naive patients (colorectal, 26%; gastric, 37%; and biliary-tract, 22%) and 19% in those previously treated (all with fluoropyrimidines). A poor performance status adversely affected the response and survival of patients. The toxicity of treatment was very mild, and occurrence of severe diarrhoea (11% of patients) and mucositis (3%) was lower than that reported with other modulations of 5-FU. A cut-off value of 24-h MTXs was identified as a strong prognostic indicator. Patients with 24-h MTXs ≤ 2 μM had a significantly better probability of response (37% versus 5%; P = 0.032), longer progression-free survival (5.3 versus 2.3 months; P = 0.023) and overall survival (10.8 versus 8.3 months; P = 0.045) on multivariate analysis. In chemotherapy-naive colorectal cancer patients, those with 24-h MTXs ≤ 2 μM had a response rate of 38% (3/8), with a 19.6-month median survival time, as compared to no responses (0/4) and a 9.9-month median survival in the group with a lower serum concentration. The achievement of such MTX serum levels yielded a 31% (4/13) response rate even in colorectal patients who had previously received a 5-FU-FA treatment.

KW - 5-Fluorouracil

KW - Double modulation

KW - Gastrointestinal carcinomas

KW - Levo-folinic acid

KW - Methotrexate

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0030249114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030249114&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(96)00155-4

DO - 10.1016/0959-8049(96)00155-4

M3 - Article

C2 - 8983280

AN - SCOPUS:0030249114

VL - 32

SP - 1719

EP - 1726

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -